Highest-materiality recent filing
Issued 400 shares of Series F Convertible Preferred Stock at $1,000 stated value each to investor Allen O. Cage Jr. for $400,000.
Reverse stock split (1:2 to 1:25) approved: 3,605,584 for, 741,154 against; board may implement before June 9, 2027.
Avalon GloboCare issues $500K in notes (18.75% OID); appoints Sam Knipper CFO, Luisa Ingargiola CSO
Issued $250K note to Dune Equity Holdings ($200K gross) and $250K note to FirstFire Global Opportunities ($200K gross), each with $50K original issue discount.
Avalon GloboCare files pro forma financials for sale of real estate unit to Chairman for $9M
Sale of Avalon RT 9 Properties to Chairman Wenzhao Lu for $9M; excess proceeds ~$2M recorded to additional paid-in capital.
Avalon Quantum AI collaborates with AWS and Caylent for Catch-Up Phase 2 development
Avalon subsidiary Avalon Quantum AI LLC collaborates with AWS to support Phase 2 of Catch-Up agentic AI video platform.
Avalon GloboCare receives Nasdaq notice of non-compliance with minimum bid price rule
Nasdaq notified Avalon GloboCare on April 15, 2026 of bid price deficiency per Listing Rule 5550(a)(2).
Avalon Globocare sets 2026 Annual Meeting for June 9; shareholder proposal deadline April 12
2026 Annual Meeting scheduled for June 9, 2026, held virtually; record date is May 15, 2026.
Avalon GloboCare shareholders approve reverse split authorization but no split planned
On March 30, 2026, shareholders approved a future reverse stock split authorization; Board not planning to implement now.
Avalon Globocare shareholders approve reverse stock split, note conversions, and Lu exchange
All 7 proposals passed at special meeting on March 30, 2026.
Avalon GloboCare corrects share count in $2.8M private placement
The amendment corrects the number of shares reported under Item 3.02 in the original March 2 filing.
Avalon Globocare awards $175K bonus to CFO, increases lead director fees to $95K/yr
CFO Luisa Ingargiola awarded $175,000 bonus for efforts during 2025 fiscal year.
Avalon GloboCare closes $3.25M private placement with up to $6.5M additional warrant proceeds
Issued 6,372,550 shares (or pre-funded warrants) at $0.51, plus Series A-1/A-2 warrants for 6,372,550 shares each at $0.51.
Avalon GloboCare subsidiary accepted into AMD AI Developer Program
Avalon Quantum AI LLC accepted into AMD AI Developer Program, gaining access to AMD Developer Cloud credits and compute resources.
Avalon Globocare issues $233,910 convertible note; three directors resign, three appointed
Note principal $233,910 (incl. $26,910 OID); net proceeds $207,000; matures Feb 15, 2027.
Avalon GloboCare sells 100% of property subsidiary to Chairman for $9M, relieved of $5.9M mortgage
Sold 100% membership interests in Avalon RT 9 Properties, LLC to Chairman Wenzhao Lu for $9M total consideration.
Avalon GloboCare subsidiary files provisional patent for audience-adaptive AI video platform
U.S. Provisional Patent Application No. 63/961,892 filed for system that generates multiple personalized commentary video variants while preserving factual integrity.
Avalon GloboCare issues $233,910 promissory note to Vanquish Funding Group at 13% OID
Principal $233,910; purchase price $207,000 (13% original issue discount); 12% one-time interest.
Avalon GloboCare converts $2.6M of debentures to common stock, slashes debt
Converted $2.6M principal from June 2024 institutional note into shares; $288K repaid in cash.
Avalon GloboCare terminates merger with YOOV Group; subsidiary files AI patent
Mutually terminated March 2025 merger agreement with YOOV Group Holding Limited, effective Jan 21, 2026.
Avalon GloboCare renews FDA registration for KetoAir; plans Q2 2026 launch via Catch-Up AI platform
FDA registration renewed for KetoAir breathalyzer (Reg. No. 3026284320) for ketogenic health management.
Avalon GloboCare regains Nasdaq minimum equity compliance, launches generative AI video platform
Nasdaq confirmed compliance with minimum stockholders' equity rule 5550(b); previous hearing cancelled.
Avalon GloboCare holds annual meeting; all director nominees elected, auditor ratified
Stockholders elected all six director nominees: Wenzhao Lu, Lourdes Felix, Steven Sanders, William Stilley III, Wilbert Tauzin II, Tevi Troy.
Avalon GloboCare touts RPM's Catch-Up generative AI video platform for KetoAir marketing
Board director Michael Mathews, also RPM CEO, discussed Catch-Up SaaS platform on ProactiveInvestors.
Acquired RPM Interactive, a generative AI SaaS platform for automated short-form video, via merger with subsidiary Avalon Quantum AI.
Avalon GloboCare reports Q3 2025 KetoAir progress: UK launch and first-responder program
Launched four-month Holistic Health Reset program for 50 first responders in Nevada using KetoAir for daily metabolic monitoring.
Avalon GloboCare receives Nasdaq delisting notice over equity deficiency
On Nov 19, 2025, Nasdaq notified Avalon GloboCare (ALBT) it is not in compliance with Listing Rule 5550(b) due to stockholders' equity of ($3,891,270) vs required $2.5M.
Avalon GloboCare reveals YOOV preliminary FY2025 revenue of $59.3M, net income $3.8M
YOOV's preliminary unaudited FY2025 (year ended March 31, 2025): revenue $59.3M, net income $3.8M (206% growth).
Avalon GloboCare raises $500K via stock sale, amends Series C preferred, and updates note balance
Issued 141,643 shares at $3.53/share to York Sun Investment for $500,000.
Avalon GloboCare to launch KetoAir breathalyzer sales in UK starting September 1, 2025
KetoAir breathalyzer sales in UK begin September 1, 2025 at www.KetoAir.uk; device measures breath acetone for ketosis tracking.
Avalon GloboCare issues 221,000 unregistered shares upon note conversion; total shares 3.69M
Issued 221,000 shares of unregistered common stock between July 30 and August 6, 2025 to a noteholder upon partial conversions of a promissory note.
Avalon GloboCare issues 393,716 unregistered shares in July 2025 for note conversions and services
211,400 shares issued July 16-17 on partial conversion of promissory note; outstanding then 3,286,793.
Avalon GloboCare extends maturity of senior secured promissory note to August 31, 2025
Waiver with Mast Hill Fund extends maturity of promissory note from June 5, 2025 to August 31, 2025.
Avalon GloboCare subsidiary signs distribution agreement with Saga Health for KetoAir breathalyzer
Q&A Distribution, LLC entered a wholesale distribution agreement with Saga Health Corporation for the KetoAir breathalyzer.
Avalon GloboCare raises $300,000 via Series C Convertible Preferred Stock private placement
Sold 300 shares of Series C Convertible Preferred Stock to Mast Hill Fund for $300,000; net proceeds $290,000 after legal fees.
Sold 121,200 shares and pre-funded warrants for 354,300 shares at $475,500; net proceeds $450,500.
Avalon GloboCare granted Hong Kong patent for CAR-T/CAR-NK cell technology
Hong Kong Intellectual Property Department issued standard patent HK40074322 for CAR-T and CAR-NK cell technology.
Avalon GloboCare issues $200K convertible notes to two accredited investors
Two convertible promissory notes of $100K each issued to Anthony Macaluso and Lawrence Bruno on July 3, 2025.
Definitive agreement for co-development of VOC nanosensor-based point-of-care cannabis breathalyzer.
Issued 141,643 common shares to York Sun Investment Holding Limited at $3.53/share for $500,000; closing expected by June 6, 2025.
Avalon GloboCare receives Nasdaq delisting notice for negative stockholders' equity
Stockholders' equity of ($3,891,270) as of March 31, 2025, below Nasdaq's $2.5M minimum.
Avalon GloboCare files S-4 for merger with YOOV; creates AIaaS company
Avalon and YOOV filed Form S-4 with SEC for proposed merger, advancing deal first announced March 7, 2025.
KetoAir breathalyzer used in BrAce 4 Impact Challenge for police chiefs, launched April 1, 2024.
Avalon GloboCare granted Chinese patent for CAR-T/NK cell technology; term 20 years
Patent CN 114502188 B issued by CNIPA, effective April 4, 2025, with 20-year protection.
Avalon GloboCare launches KetoAir challenge series with Pounds Transformation Clinics
Partnership with Pounds Transformation Clinics for 'BrAce 4 Impact Challenge Series' using KetoAir breathalyzer.
Avalon GloboCare merges with YOOV; YOOV had $45.7M revenue, $3.4M net income in 2024
YOOV CY2024 unaudited revenue $45.7M, net income $3.4M; up from $28.7M rev, ($2.4M) loss in 2023.
Avalon GloboCare redeems 40% stake in Laboratory Services MSO for $1.745M
Avalon Lab sells its 40% equity interest in Laboratory Services MSO, LLC back to the entity for $1,745,000 total consideration.
Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology
Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.
Avalon GloboCare exchanges Series A preferred for new Series D; eliminates Series A
Chairman Wenzhao Lu exchanged 9,000 Series A shares for 5,000 Series D shares; no Series A outstanding after Jan 9, 2025.
Avalon GloboCare raises up to $7M via convertible preferred stock at $2.41 conversion price
Agreement with York Sun Investment for up to 7,000 shares Series C Convertible Preferred at $1,000/share, total $7M.
Waived all amortization payments under the $2.845M senior secured note with Mast Hill Fund; paid $150k waiver fee.
On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).
On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).
Max materiality 1.00 · Median 0.55 · Most common event other_material